S11 Ep22: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS

In this episode of the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to break down the major news that addiction candidate SVN-015 has been accepted into the US NIH/NIDA Addiction Treatment Discovery Program — opening the door to fully funded preclinical work and potentially up to $3m per year in non-dilutive grants. Anthony also discusses progress across Solvonis’ CNS pipeline, the company’s AI-powered discovery engine, and the widening valuation gap between UK and US biotech markets.Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.